Investor Presentation First Nine Months of 2022
142
Investor presentation First nine months of 2022
Solid sales growth driven by Diabetes and Obesity care
DKK billion
150
Reported annual sales 2017-2021
+4.7%¹
14%
15%
16%
100
17%
16%
86%
50
50
84%
85%
83%
84%
0
2017
2018
2019
2020
2021
Diabetes and Obesity care
Rare disease
1 CAGR for 5-year period
S&D: Sales and distribution; R&D: Research and development
Note: The outlined expected developments are aspirations and not long-term financial targets
السمر
لام
Expected development towards 2025
Gross margin
Remain broadly stable
Novo NordiskⓇ
S&D cost ratio
Gradually decline enabled by
attractive sales growth
R&D cost ratio
8
88
Administration
cost ratio
Gradually increase to
expand and diversify pipeline
Decline driven by efficiency
gains
Operating
margin
Remain broadly stableView entire presentation